Sanofi appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee

David Meeker will leave the company at the end of June after a 23-year career with Genzyme and Sanofi.

Mr Sibold currently serves as head of Sanofi Genzyme's Global Multiple Sclerosis, Oncology and Immunology organization, a position he has held since January 2016 and where he has led preparation for the global launches of Dupilumab and Sarilumab. He joined Sanofi in late 2011 as head of the MS franchise where he oversaw the successful launches of Aubagio and Lemtrada. As head of Sanofi Genzyme, Mr Sibold will now lead the company's efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology.

"With a strong commitment to serving patients, Sanofi Genzyme has evolved from a rare disease company into a preeminent specialty care business, deeply rooted in science. I am confident in Bill Sibold's experience and leadership to build on this strong foundation as we chart the next chapter for Sanofi Genzyme, which has become a real growth driver for Sanofi" said Olivier Brandicourt, CEO, Sanofi. "I would also like to thank David Meeker for his tireless dedication to our shared vision for Sanofi Genzyme and his personal passion for the patients we serve, both of which helped make our company the success it is today."

Mr Sibold is from Canada and has more than twenty-five years of experience in the biopharmaceutical industry since starting his career with Eli Lilly. He held a number of leadership positions within Biogen, including driving their US commercial operations in neurology, oncology and rheumatology and general management of Biogen's Australian and Asia-Pacific business. In addition to his time with Biogen, Mr Sibold also served as the chief commercial officer of Avanir Pharmaceuticals. He holds an MBA from Harvard Business School and a BA in Molecular Biophysics and Biochemistry from Yale University.